Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Usana Health Sciences (USNA) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Usana Health Sciences (USNA) over the last 16 years, with Q3 2025 value amounting to 0.57%.

  • Usana Health Sciences' EBIT Margin fell 72200.0% to 0.57% in Q3 2025 from the same period last year, while for Sep 2025 it was 4.58%, marking a year-over-year decrease of 49700.0%. This contributed to the annual value of 7.76% for FY2024, which is 23400.0% down from last year.
  • Latest data reveals that Usana Health Sciences reported EBIT Margin of 0.57% as of Q3 2025, which was down 72200.0% from 7.09% recorded in Q2 2025.
  • Usana Health Sciences' EBIT Margin's 5-year high stood at 15.95% during Q3 2021, with a 5-year trough of 0.57% in Q3 2025.
  • For the 5-year period, Usana Health Sciences' EBIT Margin averaged around 9.78%, with its median value being 10.24% (2023).
  • As far as peak fluctuations go, Usana Health Sciences' EBIT Margin skyrocketed by 10600bps in 2023, and later crashed by -72200bps in 2025.
  • Usana Health Sciences' EBIT Margin (Quarter) stood at 14.86% in 2021, then plummeted by -33bps to 9.89% in 2022, then increased by 11bps to 10.95% in 2023, then plummeted by -65bps to 3.84% in 2024, then crashed by -85bps to 0.57% in 2025.
  • Its last three reported values are 0.57% in Q3 2025, 7.09% for Q2 2025, and 6.28% during Q1 2025.